louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01913574: Efficacy Study of Acupuncture to Treat the Upper Abdominal Pain of Cancer Patients
Official title: Pilot Study of Acupuncture to Alleviate the Upper Abdominal Pain of Cancer Patients Treated With Neurolytic Celiac Plexus Block
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Abdominal Pain
Lead sponsor: Daegu Catholic University Medical Center
Sponsor class: OTHER
First posted: 2013-08-01
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to investigate the effectiveness of acupuncture for alleviating the upper abdominal pain of cancer patients

Detailed description: Neurolytic celiac plexus block (NCPB) is a commonly performed procedure in patients with intractable pain due to malignancies involving the upper and mid abdomen. Recently, acupuncture is used as one of alternative interventions to treat cancer-related pains. This pilot study aims to investigate the effectiveness of pain-relief of acupuncture via comparing acupuncture plus NCPB with NCPB alone. Total 14 cancer patients with NCPB will be randomized into two groups of acupuncture and control.

Eligibility criteria: Inclusion Criteria:

* Age over 18 years
* Upper abdominal pain VAS ≥ 5
* Unresectable abdominal malignancy, moderate or severe abdominal pain poorly controlled with pharmacotherapy.
* All patients had advanced cancer diagnosed by histological/cytological examination
* Follow-up possible during the clinical trial
* Written informed consent voluntarily

Exclusion Criteria:

* Patient with uncorrectable coagulopathy
* Patient with allergy to local anesthesics or alcohol..
* Previous NCPB or had implanted epidural or intrathecal analgesic therapy
* Inability to lie prone
* Disease encasing the celiac plexus on computed Tomography scan
* Patients with psychiatric diseases that could have affected the study assessments
* Significant renal or hepatic disease
* Inability to comprehend or express oneself in the Korean language
* Refusal to participate in the trial or to provide informed consent

Primary outcomes:
measure: Visual analogue scale(VAS)
timeFrame: Change from baseline to 2 weeks
Secondary outcomes:
measure: Analgesic drug consumption
timeFrame: Change from baseline to 2 weeks
Other outcomes:
Locations:
city: Daegu
country: Korea, Republic of
facility: Daegu Catholic University Medical Center
state: Kyungsangbukdo
Study officials:
affiliation: Comprehensive and Integrative Medicine Institute
name: Jeong-Chul Seo, KMD, Ph.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Daegu Oriental Hospital of Daegu Haany University
name: Min-Ah Gwak, KMD, Ph.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Comprehensive and Integrative Medicine Institute
name: Seong_Hoon Park, KMD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03944174: Single Trans-sacral Screw Versus Two Iliosacral Screws
Official title: Comparative Study Between Single Trans-sacral Screw Versus Two Iliosacral Screws in Fixation of Unstable Pelvic Fractures
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pelvic Fracture
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-05-09
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patient between 18 and 60 years old with unstable pelvic fracture admitted to the trauma unit of Assiut University Hospital

Brief summary: 1. To compare Single Trans-sacral screw fixation vs. two Ilio-Sacral screws fixation as regard time for starting weight bearing.
2. To compare between functional outcome using the Majeed Pelvic Score.

Detailed description: Sacroiliac screws (SISs) have been used since Vidal et al introduced them in 1973. Since that, SIS fixation has become a common technology in fixing pelvic posterior ring injuries with important progress in the past 20 years. Currently, SIS fixation represents the only minimally invasive technique to stabilize the posterior pelvic ring. For that reason, it is steadily gaining popularity, becoming one of the most commonly used techniques. The sacrum, serving as the foundation of the spine, transmits the stress between spine and pelvis through sacroiliac joints. Thus, the goal of surgical fixation is the reconstruction of the spino-pelvic-junction to allow early weight-bearing and to facilitate nursing care, particularly for multiple injured patients.

As a result of the deforming forces acting perpendicular to the implant axis, routine ilio-sacral screws fixation may not provide adequate stabilization, especially in certain unstable injuries. Longer trans-sacral screws that traverse the entire upper sacrum and exit the contralateral iliac cortex may improve holding power and also stabilize concomitant contralateral posterior pelvic injuries. These trans-sacral screws are reliably safe to insert using routine intraoperative fluoroscopy, and they provide durable fixation.

Eligibility criteria: Inclusion Criteria:

1. Unstable pelvic fractures Tile type B \& C.
2. Sacral Fractures.
3. Recent trauma: less than 1 week from date of trauma.
4. Neurologically free.
5. Injury Severity Score (ISS) \< 18.

Exclusion Criteria:

1. Spino-pelvic dissociation.
2. Comminuted fractures
3. Bilat. Sacral fractures.
4. Sacral insufficiency.
5. Patients with associated comorbidities "eg. uncontrolled diabetes mellitus , chronic renal failure, etc.".

Primary outcomes:
measure: Early painless weight bearing as tolerated measured by Visual Analogue Scale of Pain (VAS).
timeFrame: 2 weeks
measure: To measure the functional outcome using Majeed Pelvic Score system
timeFrame: 6 weeks and 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02969174: Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.
Official title: Clinical Professor of Shanghai Tongji Hospital
Study type: EXPANDED_ACCESS
Overall status: APPROVED_FOR_MARKETING
Conditions: HDFN
Lead sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine
Sponsor class: OTHER
First posted: 2016-11-21
Sex: ALL
Minimum age (years): 12
Maximum age (years): 38
Standard ages: CHILD

Brief summary: To establish a genotyping and extraction technology of non invasive prenatal diagnosis for fetal blood group genotype from cell-free fetal DNA in peripheral blood of pregnant women.

To achieve prenatal accurate identification of fetal blood group genotypes，and provide credible theoretical evidence for the prenatal diagnosis and treatment of hemolytic disease of newborn (HDN).

Detailed description: Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.

Eligibility criteria: Inclusion Criteria:

blood samples of pregnant couples,gender/nation/region is unlimited.

Exclusion Criteria:

adipose or hemolytic samples,overdue samples,unidentified samples

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05567874: Nosocomial COVID-19 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021
Official title: Proportion of Nosocomial COVID-19 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: SARS CoV 2 Infection
Lead sponsor: Centre Hospitalier Régional Metz-Thionville
Sponsor class: OTHER
First posted: 2022-10-05
Enrollment: 216
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospitalized patients with Covid-19 infection

Brief summary: The rate of nosocomial SARS-CoV2 infections found in the different studies since the beginning of the pandemic is very variable (\<1% in hospitals in the USA to about 20% in a British hospital). Mortality related to these nosocomial SARS-CoV2 infections is higher than in the general population. The risk factors identified for this nosocomial acquisition are multiple. We were confronted with nosocomial acquisitions and cluster situations in the services, without exhaustive data to measure these phenomena, and we lacked data to consider areas for improvement.

The objectives of this study are to determine the proportion of nosocomial SARS COV 2 infections in the total number of patients hospitalized with a Covid-19 infection at the CHR Metz-Thionville in 2021, and to describe the characteristics of this population.


Eligibility criteria: Inclusion Criteria:

* Patients hospitalised at the CHR Metz-Thionville in medicine, surgery and obstetrics (MCO) or geriatric follow-up and rehabilitation care (SSR) units, in 2021 for a Covid-19 infection defined by the existence of a positive PCR result for SARS-CoV2 during the stay, or by the existence of an ICD10 code for COVID in the PMSI data of the health care establishment

Exclusion Criteria:

* Opposition to participate in the study after reading the patient information note.

Primary outcomes:
measure: Proportion of hospital-acquired infections in patients hospitalised with a covid-19 infection
timeFrame: up to 8 months after the third COVID-19 wave
Secondary outcomes:
measure: Description of the nosocomial infected population
timeFrame: up to 8 months after the third COVID-19 wave
Other outcomes:
Locations:
city: Metz
country: France
facility: CHR Metz-Thionville/Hopital de Mercy
Study officials:
affiliation: CHR Metz Thionville Hopital de Mercy
name: Mathieu LLORENS, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06804174: Comparison of Endometrial Protein Profile in Spontaneous Versus Stimulated Menstrual Cycles in Poor Responders
Official title: Distinct Endometrial Protein Profiles in Spontaneous and Stimulated Cycles in Women With Poor Ovarian Respons
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Proteome
Keywords: endometrium, proteome, poor ovarian response, spontaneous cycle, stimulated cycle
Lead sponsor: University Medical Centre Ljubljana
Sponsor class: OTHER
Collaborators: name: Slovenian Research Agency (ARRS)
First posted: 2025-02-03
Enrollment: 15
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Evaluation of endometrial protein profile in spontaneous and stimulated menstrual cycles


Eligibility criteria: Inclusion Criteria:

1. Primary infertility
2. Poor ovarian response

Exclusion Criteria:

1. Normal or high ovarian response to gonadotropin stimulation
2. Menstrual cycle disorders
3. Severe male cause of infertility
4. Preimplantation genetic testing
5. Pathological findings of the uterus (fibroids, endometrial polyps, adenomyosis) and fallopian tubes (distal occlusion of one or both fallopian tubes with hydrosalpinx).

Primary outcomes:
measure: Analysis of endometrial proteome after the use of gonadotropins
timeFrame: From enrollment to the end of treatment (approximately 2 months).
Secondary outcomes:
Other outcomes:
Locations:
city: Ljubljana
country: Slovenia
facility: Division of Obstetrics and Gynecology, university Medical Centre Ljubljana
Study officials:
affiliation: Division of Obstetrics and Gynecology, University Medical Centre Ljubljana
name: Eda Prof. Vrtačnik bokal, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT02089074: Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack
Official title: Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack: Adherence and Cardiovascular Events in the First Three Months
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ischemic Attack, Transient
Stroke
Keywords: Secondary Prevention
Pharmacists
Directive Counseling
Medication Adherence
Patient Compliance
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: St. Olavs Hospital
name: Helse Midt-Norge
name: Sykehusapotekene i Midt Norge
First posted: 2014-03-17
Enrollment: 265
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Use of drugs is an important factor in secondary prophylaxis after transient ischemic attack (TIA), but studies show that adherence to the prescribed drugs is often poor. This randomised controlled trial aims to investigate whether a systematic follow up of drug treatment using medication reconciliation, medication reviews and patient counselling by clinical pharmacists, improves adherence and/or decreases cardiovascular events the first three months and the first year after TIA. Patient satisfaction will also be compared between the two groups.


Eligibility criteria: Inclusion Criteria:

* Probable or possible transient ischemic attack
* Residing in Central Norway
* Examined within 2 weeks after the onset of symptoms
* Modified Rankin Scale 3 or less and living at home
* enrolled in the MIDNOR-TIA study NCT02038725
* Informed consent

Primary outcomes:
measure: adherence to drug treatment in secondary prevention after TIA
timeFrame: 3 months
Secondary outcomes:
measure: adherence to drug treatment in secondary prevention after TIA
timeFrame: 1 year
measure: Persistence
timeFrame: 3 months
measure: Incidence of stroke and cardiovascular events and deaths
timeFrame: 3 months
measure: degree of disability or dependence in the daily activities
timeFrame: 3 months
measure: patient satisfaction
timeFrame: 3 months
measure: Persistence
timeFrame: 1 year
measure: Incidence of stroke and cardiovascular events and deaths
timeFrame: 1 year
measure: degree of disability or dependence in the daily activities
timeFrame: 1 year
measure: patient satisfaction
timeFrame: 1 year
Other outcomes:
Locations:
city: Kristiansund
country: Norway
facility: Kristiansund Sykehus
city: Levanger
country: Norway
facility: Levanger Sykehus
city: Molde
country: Norway
facility: Molde Sykehus
city: Namsos
country: Norway
facility: Namsos Sykehus
city: Trondheim
country: Norway
facility: St Olavs Hospital
city: Ålesund
country: Norway
facility: Ålesund Sykehus
Study officials:
affiliation: Norwegian University of Science and Technology
name: Bent Indredavik, PhD, Prof
role: STUDY_DIRECTOR
References:
Clinical trial NCT01329874: Anesthetic Efficacy of Gow-Gates Versus Conventional Inferior Alveolar Nerve Block Techniques
Official title: Comparison of the Anesthetic Efficacy in Mandibular Molars With Acute Irreversible Pulpitis With Either Conventional Inferior Alveolar or Gow-gates Nerve Block Techniques Plus Buccal or Lingual Infiltration
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Anesthesia; Reaction
Pain
Lead sponsor: Mashhad University of Medical Sciences
Sponsor class: OTHER
First posted: 2011-04-06
Enrollment: 80
Sex: ALL
Minimum age (years): 12
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to determine whether Gow Gates block injection is more effective than conventional alveolar nerve block in anesthetising mandibular molars with acute pulpitis.

Detailed description: Pain management and adequate anesthesia are of critical importance for the endodontist. Traditionally, mandibular teeth are anesthetized via inferior alveolar nerve block (IAN). However, this technique provides a marginal success rate of 19-56% in patients with irreversible pulpitis.Gow Gates technique introduced in 1973 for anesthetizing of mandibular molars with more accuracy, success and safety.

Eligibility criteria: Inclusion Criteria:

* Mandibular molars with acute irreversible pulpitis

Exclusion Criteria:

* Unhealthy patients
* Patients who had taken pain killer less than 4 hours before appointment

Primary outcomes:
measure: Number of participant who will have pain following Gow gates or traditional inferior alveolar nerve block
timeFrame: 6 months
Secondary outcomes:
measure: Heart rate monitoring
timeFrame: before and after block injections (day 1)
Other outcomes:
Locations:
city: Mashhad
country: Iran, Islamic Republic of
facility: Dept of Endodontics, Faculty of Dentistry
state: Khorasan Razavi
Study officials:
affiliation: Dental Research Center, Faculty of Dentistry, Mashhad University of Medical Sciences
name: Jamileh Ghoddusi, D.D.S,M.S.c
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03183674: Oxytocin in Spectrum Autism Disorders
Official title: Oxytocin in Individuals With Spectrum Autism Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Autistic Disorder
Lead sponsor: University of Sao Paulo General Hospital
Sponsor class: OTHER
First posted: 2017-06-12
Enrollment: 80
Sex: ALL
Minimum age (years): 3
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: Observe effects of oxytocin on individuals with autism spectrum disorder

Detailed description: To observe the effects of oxytocin on individuals with autism spectrum disorder according to gender, in facial recognition and eye tracking tests. The investigators will apply the nepsy and eye tracking tests before and 45 minutes after the puff with oxytocin or placebo at the dose of 0.4 IU / kg / dose maximum of 24 IU. The next week the volunteer will return and will do the same procedure because whoever took the placebo would take oxytocin and vice versa. Is a randomized, double-blind, placebo-controlled clinical trial.

Eligibility criteria: Inclusion Criteria:Diagnosis of ASD by DSMV

* CARS\> 30
* age between 3 and 16 years
* stable (3 months with medication maintained or without medication)

Exclusion Criteria:- pregnant women, infants and

* participation in another research project of pharmacological or behavioral intervention in progress
* Use of pituitary hormones, cortisol, androgens and estrogens.
* heart problems: recent AMI, heart failure.
* respiratory problems: pneumonia, respiratory failure, decompensated asthma, acute bronchitis.

Primary outcomes:
measure: Eye tracking
timeFrame: on average of 1 year
Secondary outcomes:
measure: Nepsy
timeFrame: on average of 1 year
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Instituto de Psiquiatria
Study officials:
affiliation: Instituto de Psiquiatria
name: Debora Zambori
role: STUDY_CHAIR
References:
Clinical trial NCT01756274: Evaluation of Blood Glucose Monitoring Systems With Blood Samples From Neonates
Official title: Performance of Three Bayer Blood Glucose Monitoring Systems With Blood Samples From Neonates
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Lead sponsor: Ascensia Diabetes Care
Sponsor class: INDUSTRY
First posted: 2012-12-25
Enrollment: 162
Sex: ALL
Maximum age (years): 30
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study was to evaluate the performance of three Bayer Blood Glucose Monitoring Systems (BGMS) with neonatal blood. Blood samples used in this study were 'left-over samples'. The blood samples were from heel sticks of neonates, collected (into a tube) and sent to the laboratory. All meter Blood Glucose (BG) results were compared with capillary plasma results obtained with a reference laboratory glucose method (Cobas® 6000 instrument).


Eligibility criteria: Inclusion Criteria:

* Routine blood samples (heelstick) collected from neonates (less than 30 days of age).
* A portion of the samples (approximately 10%) will be from subjects \<24 hours old.
* A portion of the samples (at least 10%) will be from subjects in the NICU.
* Sample blood volume must be sufficient to complete investigational testing in addition to prescribed testing.

Exclusion Criteria:

* Samples from babies \>=30 days of age

Primary outcomes:
measure: Percent of Blood Glucose Results Within +/-15 mg/dL(<75 mg/dL) and Within +/-20% (>=75 mg/dL) of the Reference Instrument BG Value
timeFrame: 30 minutes
Secondary outcomes:
measure: Percent of BG Results (Per Population) Within +/-15 mg/dL (<100 mg/dL)and Within +/-15% (>=100 mg/dL) of the Reference Instrument BG Value
timeFrame: 30 minutes
Other outcomes:
measure: Number of Blood Samples From Babies Less Than 24 Hours Old That Produced Meter Results Beyond What Random Chance Would Predict (i.e. Outside 95% Limits for Studentized Residuals)
timeFrame: 30 minutes
measure: Number of Blood Samples From Babies in the Neonatal Intensive Care Unit (NICU) That Produced Meter Results Beyond What Random Chance Would Predict (i.e., Outside 95% Limits for Studentized Residuals)
timeFrame: 30 minutes
Locations:
city: St. Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Dennis J Dietzen, PhD, DABCC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00835874: Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis
Official title: Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Necrotizing Enterocolitis
Sepsis
Keywords: probiotic
preterm
lactation
breast feeding
necrotizing enterocolitis
sepsis
bacterial cultures
lactating mother
breast feeding of at least 50% of enteric feeding volume
Infant, very low birth weight
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2009-02-04
Enrollment: 57
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: We hypothesize that supplementing maternal diet with probiotics will decrease the incidence of feeding intolerance, necrotizing enterocolitis and sepsis in preterm infants fed breastmilk.

Detailed description: Oral probiotics have previously been shown to prevent necrotizing enterocolitis in preterm infants. A few reports of sepsis by a probiotic bacteria have impeded implementation of oral probiotic supplementation in most NICUs. Considering the proven immunomodulatory effect of maternal probiotics on breastfed infants of atopic mothers, we would like to explore the indirect effects of maternal probiotics on preterm infants

Eligibility criteria: Inclusion Criteria:

* Mothers of preterm infants
* Pumping breast milk

Exclusion Criteria:

* Neonatal congenital anomalies

Primary outcomes:
measure: all cause mortality at three months of age
timeFrame: 3 months
measure: incidence and severity of necrotizing enterocolitis by Bell's staging at Three months
timeFrame: 3 months
measure: occurrence of bacterial or fungal infection per blood,csf or urine cultures at three months
timeFrame: 3 months
Secondary outcomes:
measure: incidence of BPD, PVL, ROP
timeFrame: 36 weeks
measure: maternal adverse effects during treatment
timeFrame: 3 months
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv Medical Center
Study officials:
affiliation: Tel Aviv Medical Center
name: Shaul Dollberg
role: PRINCIPAL_INVESTIGATOR
affiliation: Tel Aviv Medical Center
name: Shira Benor
role: STUDY_DIRECTOR
References:
citation: Benor S, Marom R, Ben Tov A, Armoni Domany K, Zaidenberg-Israeli G, Dollberg S. Probiotic supplementation in mothers of very low birth weight infants. Am J Perinatol. 2014 Jun;31(6):497-504. doi: 10.1055/s-0033-1353490. Epub 2013 Aug 9.